Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Besivance · 1 trial · 1 indication
Ocular Treatment-Emergent Adverse Events on the Study Eye
Non-Ocular Treatment-Emergent Adverse Events on the Study Eye
| Arm | Type | Description |
|---|---|---|
| Besivance | EXPERIMENTAL | besifloxacin ophthalmic suspension 0.6% |
| Vehicle | PLACEBO_COMPARATOR | Vehicle of Besivance |
| Name | Type | Description |
|---|---|---|
| Besivance | DRUG | Ocular administration to affected eye for 7 days |
| Vehicle | DRUG | Vehicle of Besivance administered to affected eye for 7 days |
Inclusion Criteria: * Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge (crusty or sticky eyelids) and redness in at least one eye. * Subjects who are willing to discontinue contact lens wear for the duration of the study. * Subjec...
Besivance is a small molecule drug developed by Bausch + Lomb Corporation for the treatment of bacterial conjunctivitis and congenital nasolacrimal duct obstruction. It is an ophthalmic suspension containing besifloxacin 0.6%.
Besivance is developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of bacterial conjunctivitis and congenital nasolacrimal duct obstruction.
Besivance is in Phase 3 clinical development for bacterial conjunctivitis, with a completed Phase 3 trial. It is also being studied in a Phase 1 trial for congenital nasolacrimal duct obstruction. Besivance is investigational and not yet approved by the FDA.
Besivance has been studied in two completed clinical trials. NCT01175590 was a Phase 3, randomized, double-blind, placebo-controlled trial in 518 patients with bacterial conjunctivitis. NCT01431170 was a Phase 1 trial in 24 children with congenital nasolacrimal duct obstruction.
Besivance is the brand name for besifloxacin ophthalmic suspension 0.6%. The drug contains the active ingredient besifloxacin, which is a fluoroquinolone antibiotic used to treat bacterial infections of the eye.